SISRAM MED1696.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, SISRAM MED (1696.HK) trades at a P/E of 9.63x, P/B of 0.23x, P/S of 0.29x, and a dividend yield of 5.22%.
Longitudinal percentile comparison: P/E sits at the 24th percentile over the trailing 10Y window (vs. 55th percentile over 3Y); P/B sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 28th percentile within its industry and the 44th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 5.30%, ranking at the 100th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 23.9 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. SISRAM MED operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 1696 · SEHK: 1696 · 1696
Want the full picture on whether SISRAM MED (1696.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 9.63 | ||||||
| P/B (MRQ) | 0.23 | ||||||
| P/S (TTM) | 0.29 | ||||||
| Dividend Yield | 5.22% | ||||||
| Buyback + Div Yield | 5.30% |